Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation

Transplant International

Volumn 24, Issue 8, 2011, Pages 787-796

  Cucchetti, Alessandro ^a   Cescon, Matteo ^a   Ercolani, Giorgio ^a   Morelli, Maria Cristina ^a   Del Gaudio, Massimo ^a   Zanello, Matteo ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cirrhosis; hepatic resection; hepatocellular carcinoma; liver transplantation; simulation model

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; FEMALE; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIMULATION;

AGED; CARCINOMA, HEPATOCELLULAR; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; END STAGE LIVER DISEASE; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; TREATMENT OUTCOME;

EID: 79960122752     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01276.x     Document Type: Article

References (44)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KAl,. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817.
2. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11: 1.
3. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200.
4. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229.
5. Cucchetti A, Piscaglia F, Caturelli E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413.
6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J,. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373.
7. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429.
8. Lencioni R, Crocetti L, De Simone P, Filipponi Fl,. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int 2010; 23: 698. PMID: 20492618.
9. Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010; 21: 326.
10. Sherman M,. Screening for hepatocellular carcinoma. Hepatol Res 2007; 37 (Suppl. 2): S152.
11. Trevisani F, De Notaris S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734.
12. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291. PMID: 20483497
13. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
14. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250: 922.
15. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567.
16. Teh SH, Christein J, Donohue J, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005; 9: 1207.
17. Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006; 12: 966.
18. UNOS. United Network for Organ Sharing Policy 3.6.4.4. Available at:. Accessed on May 1, 2010.
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 4210.
20. Bruix J, Sherman M,. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208.
21. Committee of the International Hepato-Pancreato-Biliary Association, IHPBA Brisbane. Terminology of Liver Anatomy and Resections, Vol. 2. Abingdon, UK: Taylor & Francis, 2000: 333 pp.
22. OPTN. 2008 Annual Report. Available at: http://www.optn.org/data/ annualReport.asp. Accessed on September 15, 2010.
23. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217.
24. UNOS/OPTN. Modifications to policy 3.6.4.4 (Liver candidates with hepatocellular carcinoma). 3.6. Allocation of Livers. Available at: http://www.unos.org/PoliciesandBylaws2/policies/docs/policy8.doc. Accessed on July 1, 2010.
25. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262.
26. Llovet JM, Brú C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329.
27. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9: 970.
28. Ridolfi L, Alvaro N, Campione T, Zaza G, Bonanno M,. The Donor Action Project: a valuable tool to measure quality and efficacy of the donation process in Emilia-Romagna. Transplant Proc 2010; 42: 150.
29. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783.
30. Freeman RB, Edwards EB, Harper AM,. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416.
31. Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003; 238: 315.
32. Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I,. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005; 11: 1242.
33. Park YK, Kim BW, Wang HJ, Kim MW,. Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. Transplant Proc 2009; 41: 1691.
34. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231.
35. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738.
36. Moya A, Berenguer M, Aguilera V, et al. Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl 2002; 8: 1020.
37. Majno PE, Sarasin FP, Mentha G, Hadengue A,. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31: 899.
38. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A,. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073.
39. Cucchetti A, Vitale A, Del Gaudio M, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010; 10: 619.
40. Llovet JM, Bruix J, Gores GJ,. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019.
41. Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008; 8: 1177.
42. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238: 885.
43. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004; 10: 1294.
44. Cillo U, Vitale A, Volk ML, et al. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010; 42: 642.